ARTICLE | Company News
EMA to review lurasidone for schizophrenia
October 26, 2012 12:59 AM UTC
Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said EMA accepted for review an MAA for lurasidone to treat schizophrenia. Takeda has exclusive rights from Dainippon to commercialize the product for schizophrenia and bipolar disorder in the EU, Norway, Russia, Switzerland and Turkey. Dainippon markets the product under the name Latuda in the U.S. and Canada for schizophrenia. ...